Daniel Lippis Sells 1,019 Shares of Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction on Monday, April 6th. The shares were sold at an average price of $80.98, for a total transaction of $82,518.62. Following the completion of the sale, the vice president directly owned 33,934 shares of the company’s stock, valued at approximately $2,747,975.32. The trade was a 2.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded up $0.11 on Monday, reaching $81.16. 2,377,061 shares of the stock were exchanged, compared to its average volume of 4,592,800. The stock has a market cap of $46.79 billion, a PE ratio of 44.35, a PEG ratio of 2.11 and a beta of 0.95. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89. The firm has a fifty day moving average price of $81.59 and a two-hundred day moving average price of $81.89.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The firm had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm’s revenue was up 13.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the third quarter worth approximately $25,000. MV Capital Management Inc. acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $26,000. Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $27,000. True Wealth Design LLC lifted its position in shares of Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after purchasing an additional 259 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $28,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on EW. Wells Fargo & Company upped their target price on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. TD Cowen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. The Goldman Sachs Group reissued a “buy” rating and issued a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Canaccord Genuity Group set a $87.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Wednesday, December 17th. Finally, UBS Group reissued a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus price target of $95.96.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.